[ad_1]
Local IV producers are asking the Ghana health service to stop using imported IV products.
They argue that such products pose serious risks to the health of patients.
Intravenous or intravenous products are health products such as liquids, drugs or blood that are infused directly into the circulatory system by a vein.
Although some of these products are domestically produced, most of the products used by most establishments in the country are imported.
Professor Gladys Amponsah, director of a local manufacturing company, Intravenous Infusions PLC, said that the quality of imported products may not have been easy to determine because of the limited information available .
According to her, the safest plan is for health agencies in Ghana to obtain the product from local manufacturers whose productions are controlled by the regulatory authorities.
"These imported products, you do not know how they are manufactured, what quality badurance measures are put in place or who are the regulators, while the products manufactured by Intravenous Infusions are known because we have an insurance manager quality. every year at the factory to inspect, give their recommendations and what they are not happy about and we comply. "
Professor Gladys Amponsah also argued that although imported products may be cheaper than domestically produced, they may be problematic for patients who may receive ineffective products.
"Price is the key for everyone. You can give a cheaper product to a patient, but the consequences can be more expensive for the patient, "she warned.
At the same time, Intravenous Infusions PLC achieved a strong performance in 2018, with sales up by more than 23.4% to reach 20.21 million GH ¢, against 16.37 million GH ¢ in 2017.
Mr. David Klutse, Managing Director of Intravenous Infusion PLC, stated that after-tax operating income increased 4% to 2.84 million GH ¢, compared with 2.73 million GH ¢ l. ;last year.
At the company's annual general meeting in Accra, Klutse said the reports communicated to stakeholders indicated that they were firmly on track and meeting their commitments in the public offering. initial.
He added that the company has also identified six strategic priorities that it believes would contribute to its success.
"We are taking steps to increase the efficiency and effectiveness of our work methods. In addition, we are adapting production capacity to our ever-changing product line, "he added.
Mr Klutse said that the progress made during the year under review highlighted the benefits of the strategic choices made in society in recent years to sustainably strengthen its capabilities.
"We expect the company to make positive progress in the coming year as we are able to generate strong returns for our valued shareholders," he added.
— living room
Source link
